Trial · NCT00153101
Results by group97
Each measurement the trial posted, group by group, in the words and numbers it posted.
21 to 40 of 97
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| ONTARGET. Doubling of Serum Creatinine in Diabetic Nephropathy Patients | Ramipril (ONTARGET) | 23 | participants | ||
| ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients | Telmisartan/Ramipril (ONTARGET) | 30 | participants | ||
| ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients | Telmisartan (ONTARGET) | 24 | participants | ||
| ONTARGET. Progression to End Stage Renal Disease (ESRD) in Diabetic Nephropathy Patients | Ramipril (ONTARGET) | 32 | participants | ||
| ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients | Telmisartan/Ramipril (ONTARGET) | 75 | participants | ||
| ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients | Telmisartan (ONTARGET) | 92 | participants | ||
| ONTARGET. All-cause Mortality in Diabetic Nephropathy Patients | Ramipril (ONTARGET) | 83 | participants | ||
| ONTARGET. Doubling of Serum Creatinine | Telmisartan/Ramipril (ONTARGET) | 167 | participants | ||
| ONTARGET. Doubling of Serum Creatinine | Telmisartan (ONTARGET) | 160 | participants | ||
| ONTARGET. Doubling of Serum Creatinine | Ramipril (ONTARGET) | 149 | participants | ||
| ONTARGET. Progression to ESRD | Telmisartan/Ramipril (ONTARGET) | 79 | participants | ||
| ONTARGET. Progression to ESRD | Telmisartan (ONTARGET) | 67 | participants | ||
| ONTARGET. Progression to ESRD | Ramipril (ONTARGET) | 71 | participants | ||
| ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients | Telmisartan/Ramipril (ONTARGET) | 108 | participants | ||
| ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients | Telmisartan (ONTARGET) | 119 | participants | ||
| ONTARGET. 3-fold Composite Endpoint of Doubling of Serum Creatinine, Progression to End Stage Renal Disease (ESRD) and All-cause Mortality in Diabetic Nephropathy Patients | Ramipril (ONTARGET) | 112 | participants | ||
| ONTARGET. New Microalbuminuria | Telmisartan/Ramipril (ONTARGET) | 763 | participants | ||
| ONTARGET. New Microalbuminuria | Telmisartan (ONTARGET) | 799 | participants | ||
| ONTARGET. New Microalbuminuria | Ramipril (ONTARGET) | 869 | participants | ||
| ONTARGET. New Macroalbuminuria | Telmisartan/Ramipril (ONTARGET) | 205 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00153101/results?page=2